Glycoprotein IIb/IIIa receptor antagonists and risk of bleeding: A single-center experience in 1020 patients

Journal of Clinical Pharmacology

Volumn 44, Issue 11, 2004, Pages 1328-1332

  Ali, Arshad ^a,b   Hashem, Mustafa ^a   Rosman, Howard S ^a   Moser, Lynette ^a   Rehan, Arshad ^a   Davis, Thomas ^a   Romanelli, Michael ^a   LaLonde, Thomas ^a   Yamasaki, Hiroshi ^a   Barbish, Brian ^a   Michael, Julia ^a   Ali, Shamsa A ^a   Schreiber, Theodore L ^a   Gardin, Julius M ^a  

^a ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^b GUTHRIE RESEARCH INSTITUTE   (United States)

Author keywords

Abciximab; Eptifibatide; Percutaneous coronary intervention (PCI); Tirofiban

Indexed keywords

ABCIXIMAB; CREATININE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE HEART INFARCTION; ADULT; AGING; ARTICLE; BLEEDING; BODY WEIGHT; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; EPISTAXIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HEMATURIA; HEMOPERICARDIUM; HUMAN; LENGTH OF STAY; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL VASCULAR DISEASE; RETROPERITONEAL HEMORRHAGE; RISK; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; HEMORRHAGE; HOSPITALS, COMMUNITY; HUMANS; MALE; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; RISK;

EID: 6344263533     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004269559     Document Type: Article

References (15)

1. EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
2. The CAPTURE Investigators. Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
3. The PURSUIT Trial Investigators. Inhibition of the platelet glycoprotein IIb/IIIa with epitifibatide in patients with acute coronary syndromes. N Engl J Med. 1998;339:436-443.
4. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
5. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
6. Bovill EG, Terrin ML, Stump DC, et al, for the TIMI Investigators. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Ann Intern Med. 1991;115:256-265.
7. Khanlou H, Tsiodras S, Eiger G, et al. Fatal alveolar hemorrhage and abciximab therapy for acute myocardial infarction. Cathet Cardiovasc Diag. 1998;44:313-316.
8. Ali A, Patil S, Grady KJ, Schreiber TL. Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: a nemesis of platelet glycoprotein IIb/IIIa inhibitors. Cathet Cardiovasc Intervent. 2000;49:181-184.
9. Aguirre F, Topol EJ, Ferguson JJ, et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 1995;91:2882-2890.
10. Peterson JG, Lauer MA, Sapp SK, Topol EJ. Heparin use is required for clinical benefit of GIIb/IIIa inhibitor eptifibatide in acute coronary syndromes: insights from the PURSUIT Trial. Circulation. 1998;98(suppl I):I-360.
11. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized, placebo-controlled trial. Lancet. 2000;356:2037-2044.
12. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM. Beta-blocker therapy in acute myocardial infarction: evidence for underutilization in the elderly. Am J Med. 1992;93:605-610.
13. McLaughlin TJ, Soumerai SB, Willison DJ, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction. Arch Intern Med. 1996;156:799-805.
14. The REPLACE 2 Investigators. AHA Scientific Session 2002.
15. Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol. 2003;41:26-32.